Baxter launches recall

DEERFIELD - Baxter International Inc. announced that a voluntary recall of all manufactured lots of Hylenex recombinant, a substance used in conjunction with human injections, has been initiated.

The recall is a precautionary measure reacting to instances of particulate matter observed in a limited number of Hylenex vials during routine stability testing, Baxter said.

Baxter is working Halozyme Therapeutics, one of the drug's developers, to investigate the root cause of the issue and appropriately address the situation.

To date, no medical events or customer complaints associated with this issue have been reported. Baxter estimates there are approximately 3,500 vials in the marketplace.